ResearchDx pushes into the Middle East for diagnostics development

ResearchDx, one of the few outfits devoted to contract test making, has extended its operation to include the Middle East, a region the company said is home to a growing biotech market.

Taking to Dubai, Research Dx said it can help local drugmakers develop diagnostics to help target their in-development therapies, providing an option that is more efficient than going it alone. Furthermore, the company offers offers lab validation services, assisting clients in obtaining the CLIA, CAP or ISO certifications they need to do business in the West, co-founder Principal Matthew Moore said.

"In addition, as the leading contract diagnostics organization, ResearchDx can provide strategic partnerships to Middle Eastern biopharmaceutical and diagnostic companies looking to develop companion diagnostics or in vitro diagnostic products for the local, U.S. or European markets," Moore said in a statement.

ResearchDx's Middle Eastern gambit comes on the heels of the company's move to focus on India last fall. Prior to that, the California operation cut the ribbon on a 30,000-square-foot facility in Irvine, increasing its footprint to provide services from assay conceptualization, discovery, optimization and validation to regulatory approvals.

For years, diagnostics development has largely been the domain of drugmakers with in-house testing capabilities, like Roche ($RHHBY) and Abbott Laboratories ($ABT), and pure-play diagnostics outfits like Qiagen ($QGEN) and bioMérieux. But ResearchDx is betting that the escalating demand for personalized medicine will outstrip the capacity of current market players, creating an avenue for contractors to step in and develop tests with speed and efficiency.

- read the statement

Suggested Articles

WuXi AppTec has cut the ribbon on its expanded Laboratory Testing Division in New Jersey as it looks to boost its integrated testing service portfolio.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.